The verdict
Our read at a glance.
Whether pexiganan's antimicrobial-peptide mechanism and its diabetic-foot trials support its use, given that the Phase 3 trials did not show benefit over standard treatment.
- The signal
- Pexiganan was studied as a topical treatment for mildly infected diabetic foot ulcers in large Phase 3 trials, which did not show it was better than oral antibiotics. It was not approved, and its development as a drug stalled. It illustrates the difficulty of turning antimicrobial peptides into approved treatments.
- The unknown
- Whether antimicrobial peptides like pexiganan can find a setting where they clearly help, and how to overcome the stability, delivery, and trial-design problems that have limited the class.
- Our read
- A real attempt to make an antimicrobial peptide into a drug that did not pan out, not a proven treatment. Pexiganan's mechanism is genuine, but its Phase 3 trials failed to beat standard care, so it stands more as a cautionary example than a usable product.
The mechanism
How it works.
Pexiganan is a synthetic 22-amino-acid antimicrobial peptide, an analog of magainin, a peptide found in frog skin. Like other cationic antimicrobial peptides, it is positively charged and inserts into the negatively charged outer membrane of bacteria, punching holes that collapse the membrane and kill the cell directly, which makes resistance harder to develop. It was formulated as a topical cream to clear bacteria in infected diabetic foot ulcers, but its Phase 3 trials did not show it worked better than standard oral antibiotics.
Safety & regulatory boundary
The consequential part.
Pexiganan is not an approved drug, and its Phase 3 trials did not show benefit over standard care. It was studied only as a topical treatment under medical supervision. Research-labeled or compounded pexiganan is not an approved product, and the antimicrobial-peptide concept does not validate broad infection or wellness claims.
What's next
What we're watching.
Whether any antimicrobial-peptide drug, including reformulated pexiganan, reaches approval, and in what setting.
Context
Why this is discussed.
Pexiganan is a prominent test of whether antimicrobial peptides can become real drugs, and its failure is often cited in discussions of why that class has been hard to develop.
The evidence base
16 cited references.
Registered trials4
ClinicalTrials.gov · PHASE3 · COMPLETED · 1994-08
ClinicalTrials.gov · PHASE3 · COMPLETED · 1994-08
ClinicalTrials.gov · PHASE3 · COMPLETED · 2014-06
ClinicalTrials.gov · PHASE3 · COMPLETED · 2014-06
Indexed literature (PubMed)12
Lamb HM et al. · Drugs · 1998
Cohen H et al. · ACS Omega · 2023
Dumville JC et al. · Cochrane Database Syst Rev · 2017
Islam K et al. · IDrugs · 1998
Elnaggar MG et al. · Biomaterials · 2020
Lee DK et al. · Biochemistry · 2013
Fuchs PC et al. · Antimicrob Agents Chemother · 1998
Adv Skin Wound Care · Adv Skin Wound Care · 2014
Gottler LM et al. · Biochim Biophys Acta · 2009
Monteiro C et al. · Mol Pharm · 2015
Denardi LB et al. · Braz J Microbiol · 2022
You Y et al. · Amino Acids · 2023
Keep reading